Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer

被引：58

作者：

Flank, Jacqueline ^{[1
,2
]}

Robinson, Paula D. ^{[3
]}

Holdsworth, Mark ^{[4
]}

Phillips, Robert ^{[5
,6
]}

Portwine, Carol ^{[7
]}

Gibson, Paul ^{[8
]}

Maan, Cathy ^{[8
]}

Stefin, Nancy ^{[7
]}

Sung, Lillian ^{[9
,10
]}

Dupuis, L. Lee ^{[1
,2
,10
]}

机构：

[1] Hosp Sick Children, Dept Pharm, Toronto, ON, Canada

[2] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada

[3] Pediat Oncol Grp Ontario, Toronto, ON, Canada

[4] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA

[5] Leeds Childrens Hosp, Reg Dept Haematol & Oncol, Leeds, W Yorkshire, England

[6] Univ York, Ctr Reviews & Disseminat, York, N Yorkshire, England

[7] McMaster Univ, Dept Pediat, Div Hematol Oncol, Hamilton, ON, Canada

[8] Childrens Hosp, Pediat Hematol Oncol, London Hlth Sci Ctr, London, ON, Canada

[9] Hosp Sick Children, Dept Pediat, Div Haematol Oncol, Toronto, ON, Canada

[10] Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada

来源：

PEDIATRIC BLOOD & CANCER | 2016年 / 63卷 / 07期

基金：

英国医学研究理事会;

关键词：

chemotherapy-induced nausea; chemotherapy-induced vomiting; clinical practice guideline; supportive care; HIGHLY EMETOGENIC CHEMOTHERAPY; DOUBLE-BLIND; ANTINEOPLASTIC MEDICATION; APREPITANT; EMESIS; ADOLESCENTS; OLANZAPINE; EFFICACY; GRADE; RECOMMENDATIONS;

D O I：

10.1002/pbc.25955

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This clinical practice guideline provides an approach to the treatment of breakthrough chemotherapy-induced nausea and vomiting (CINV) and the prevention of refractory CINV in children. It was developed by an international, interprofessional panel and is based on systematic literature reviews. Evidence-based interventions for the treatment of breakthrough and prophylaxis of refractory CINV are recommended. Gaps in the evidence used to support the recommendations made in this clinical practice guideline were identified. The contribution of these recommendations to breakthrough and refractory CINV control in children requires prospective evaluation. (C) 2016 Wiley Periodicals, Inc.

引用

页码：1144 / 1151

页数：8

共 37 条

[21] Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC) [J].

Hesketh, Paul J. ;

Morrow, Gary ;

Komorowski, Anna W. ;

Ahmed, Raza ;

Cox, David .

SUPPORTIVE CARE IN CANCER, 2012, 20 (10) :2633-2637

[22] PRONOUNCED ANTI-EMETIC ACTIVITY OF THE ANTIPSYCHOTIC DRUG LEVOMEPROMACINE (L) IN PATIENTS RECEIVING CANCER-CHEMOTHERAPY [J].

HIGI, M ;

NIEDERLE, N ;

BIERBAUM, W ;

SCHMIDT, CG ;

SEEBER, S .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1980, 97 (01) :81-86

[23] Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes [J].

Kaiser, R ;

Sezer, O ;

Papies, A ;

Bauer, S ;

Schelenz, C ;

Tremblay, PB ;

Possinger, K ;

Roots, I ;

Brockmöller, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2805-2811

[24] Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial [J].

Kang, Hyoung Jin ;

Loftus, Susan ;

Taylor, Arlene ;

DiCristina, Cara ;

Green, Stuart ;

Zwaan, Christian Michel .

LANCET ONCOLOGY, 2015, 16 (04) :385-394

[25]

Lau Moon Lin M, DRUG SAFETY IN PRESS

[26] Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: Comparison between elderly and non-elderly patient response [J].

Massa, Elena ;

Astara, Giorgio ;

Madeddu, Clelia ;

Dessi, Mariele ;

Loi, Carla ;

Lepori, Stefano ;

Mantovani, Giovanni .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 70 (01) :83-91

[27]

McCabe HL, 2003, ANTICANCER RES, V23, P5209

[28]

Multinational Association of Supportive Care in Cancer, MASCC ESMO ANT GUID

[29] Palonosetron (AloxiA®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy [J].

Musso, Maurizio ;

Scalone, Renato ;

Bonanno, Vincenza ;

Crescimanno, Alessandra ;

Polizzi, Vita ;

Porretto, Ferdinando ;

Bianchini, Carlo ;

Perrone, Tania .

SUPPORTIVE CARE IN CANCER, 2009, 17 (02) :205-209

[30]

National Comprehensive Cancer Network, ANT

← 1 2 3 4 →